Agilent Technologies, Inc. (0HAV.L)
USD 101.8
(-8.59%)
USD 101.8
(-8.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.14 Billion USD | -33.28% |
| 2022 | 1.71 Billion USD | 37.83% |
| 2021 | 1.24 Billion USD | 35.62% |
| 2020 | 918 Million USD | -10.44% |
| 2019 | 1.02 Billion USD | 328.79% |
| 2018 | -448 Million USD | 32.83% |
| 2017 | -667 Million USD | -76.92% |
| 2016 | -377 Million USD | -8.33% |
| 2015 | -348 Million USD | -30.83% |
| 2014 | -266 Million USD | -1208.33% |
| 2013 | 24 Million USD | 118.18% |
| 2012 | 11 Million USD | 100.82% |
| 2011 | -1.34 Billion USD | -228.79% |
| 2010 | 1.04 Billion USD | 145.18% |
| 2009 | 425 Million USD | -40.97% |
| 2008 | 720 Million USD | 175.86% |
| 2007 | 261 Million USD | 134.25% |
| 2006 | -762 Million USD | 65.77% |
| 2005 | -2.22 Billion USD | -91.07% |
| 2004 | -1.16 Billion USD | -154.92% |
| 2003 | -457 Million USD | 34.15% |
| 2002 | -694 Million USD | 40.38% |
| 2001 | -1.16 Billion USD | -31.38% |
| 2000 | -886 Million USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.22 Billion USD | 26.16% |
| 2024 Q1 | 971 Million USD | -15.2% |
| 2024 Q3 | 1.15 Billion USD | 9.14% |
| 2023 Q2 | 1.55 Billion USD | -9.47% |
| 2023 Q4 | 1.14 Billion USD | -21.58% |
| 2023 Q3 | 1.46 Billion USD | -6.29% |
| 2023 Q1 | 1.72 Billion USD | 0.29% |
| 2023 FY | 1.14 Billion USD | -33.28% |
| 2022 Q3 | 1.84 Billion USD | 7.1% |
| 2022 Q4 | 1.71 Billion USD | -6.79% |
| 2022 FY | 1.71 Billion USD | 37.83% |
| 2022 Q1 | 1.61 Billion USD | 29.88% |
| 2022 Q2 | 1.71 Billion USD | 6.31% |
| 2021 Q2 | 1.55 Billion USD | 32.65% |
| 2021 Q1 | 1.17 Billion USD | 27.45% |
| 2021 FY | 1.24 Billion USD | 35.62% |
| 2021 Q4 | 1.24 Billion USD | -12.94% |
| 2021 Q3 | 1.43 Billion USD | -7.86% |
| 2020 Q1 | 1.23 Billion USD | 20.59% |
| 2020 Q2 | 1.16 Billion USD | -5.83% |
| 2020 Q3 | 965 Million USD | -17.1% |
| 2020 Q4 | 918 Million USD | -4.87% |
| 2020 FY | 918 Million USD | -10.44% |
| 2019 FY | 1.02 Billion USD | 328.79% |
| 2019 Q4 | 1.02 Billion USD | 3006.06% |
| 2019 Q1 | -259 Million USD | 42.19% |
| 2019 Q2 | -357 Million USD | -37.84% |
| 2019 Q3 | 33 Million USD | 109.24% |
| 2018 Q3 | -332 Million USD | 62.95% |
| 2018 FY | -448 Million USD | 32.83% |
| 2018 Q1 | -742 Million USD | -11.24% |
| 2018 Q2 | -896 Million USD | -20.75% |
| 2018 Q4 | -448 Million USD | -34.94% |
| 2017 FY | -667 Million USD | -76.92% |
| 2017 Q3 | -482 Million USD | -39.31% |
| 2017 Q2 | -346 Million USD | -38.96% |
| 2017 Q1 | -249 Million USD | 33.95% |
| 2017 Q4 | -667 Million USD | -38.38% |
| 2016 Q2 | -250 Million USD | -26.26% |
| 2016 FY | -377 Million USD | -8.33% |
| 2016 Q1 | -198 Million USD | 43.1% |
| 2016 Q4 | -377 Million USD | -20.83% |
| 2016 Q3 | -312 Million USD | -24.8% |
| 2015 Q3 | -420 Million USD | 22.37% |
| 2015 Q1 | -460 Million USD | -72.93% |
| 2015 Q4 | -348 Million USD | 17.14% |
| 2015 FY | -348 Million USD | -30.83% |
| 2015 Q2 | -541 Million USD | -17.61% |
| 2014 FY | -266 Million USD | -1208.33% |
| 2014 Q1 | -47 Million USD | -295.83% |
| 2014 Q4 | -266 Million USD | -52.0% |
| 2014 Q3 | -175 Million USD | 31.91% |
| 2014 Q2 | -257 Million USD | -446.81% |
| 2013 FY | 24 Million USD | 118.18% |
| 2013 Q4 | 24 Million USD | -93.53% |
| 2013 Q1 | -89 Million USD | -909.09% |
| 2013 Q2 | -163 Million USD | -83.15% |
| 2013 Q3 | 371 Million USD | 327.61% |
| 2012 Q2 | -1.71 Billion USD | -16.07% |
| 2012 FY | 11 Million USD | 100.82% |
| 2012 Q4 | 11 Million USD | -96.22% |
| 2012 Q3 | 291 Million USD | 116.93% |
| 2012 Q1 | -1.48 Billion USD | -10.36% |
| 2011 FY | -1.34 Billion USD | -228.79% |
| 2011 Q4 | -1.34 Billion USD | -43.84% |
| 2011 Q3 | -933 Million USD | -12.27% |
| 2011 Q2 | -831 Million USD | -66.53% |
| 2011 Q1 | -499 Million USD | -147.89% |
| 2010 FY | 1.04 Billion USD | 145.18% |
| 2010 Q3 | 1.36 Billion USD | 448.79% |
| 2010 Q2 | 248 Million USD | -42.33% |
| 2010 Q1 | 430 Million USD | 1.18% |
| 2010 Q4 | 1.04 Billion USD | -23.44% |
| 2009 Q2 | 754 Million USD | -10.45% |
| 2009 Q1 | 842 Million USD | 16.94% |
| 2009 FY | 425 Million USD | -40.97% |
| 2009 Q3 | 674 Million USD | -10.61% |
| 2009 Q4 | 425 Million USD | -36.94% |
| 2008 Q3 | 675 Million USD | 1.66% |
| 2008 Q2 | 664 Million USD | -10.39% |
| 2008 FY | 720 Million USD | 175.86% |
| 2008 Q4 | 720 Million USD | 6.67% |
| 2008 Q1 | 741 Million USD | 183.91% |
| 2007 Q2 | -550 Million USD | 6.78% |
| 2007 Q4 | 261 Million USD | 1764.29% |
| 2007 FY | 261 Million USD | 134.25% |
| 2007 Q1 | -590 Million USD | 22.57% |
| 2007 Q3 | 14 Million USD | 102.55% |
| 2006 Q1 | -1.23 Billion USD | 44.43% |
| 2006 FY | -762 Million USD | 65.77% |
| 2006 Q4 | -762 Million USD | -1.74% |
| 2006 Q3 | -749 Million USD | 35.26% |
| 2006 Q2 | -1.15 Billion USD | 6.47% |
| 2005 Q3 | -1.63 Billion USD | -6.32% |
| 2005 Q4 | -2.22 Billion USD | -36.4% |
| 2005 Q1 | -1.33 Billion USD | -14.42% |
| 2005 Q2 | -1.53 Billion USD | -15.15% |
| 2005 FY | -2.22 Billion USD | -91.07% |
| 2004 Q2 | -692 Million USD | -31.06% |
| 2004 Q1 | -528 Million USD | -15.54% |
| 2004 FY | -1.16 Billion USD | -154.92% |
| 2004 Q3 | -787 Million USD | -13.73% |
| 2004 Q4 | -1.16 Billion USD | -48.03% |
| 2003 FY | -457 Million USD | 34.15% |
| 2003 Q4 | -457 Million USD | -63.21% |
| 2003 Q3 | -280 Million USD | 26.89% |
| 2003 Q1 | -604 Million USD | 12.97% |
| 2003 Q2 | -383 Million USD | 36.59% |
| 2002 Q2 | -1.08 Billion USD | -4.53% |
| 2002 Q3 | -955 Million USD | 11.98% |
| 2002 Q4 | -694 Million USD | 27.33% |
| 2002 FY | -694 Million USD | 40.38% |
| 2002 Q1 | -1.03 Billion USD | 10.82% |
| 2001 Q4 | -1.16 Billion USD | -467.8% |
| 2001 Q3 | -205 Million USD | -469.44% |
| 2001 Q2 | -36 Million USD | -129.27% |
| 2001 FY | -1.16 Billion USD | -31.38% |
| 2001 Q1 | 123 Million USD | 113.88% |
| 2000 Q1 | -371 Million USD | 0.0% |
| 2000 Q2 | -880 Million USD | -137.2% |
| 2000 Q3 | -574 Million USD | 34.77% |
| 2000 FY | -886 Million USD | 0.0% |
| 2000 Q4 | -886 Million USD | -54.36% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 1212.18% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 3767.873% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -478.093% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -3491.03% |
| bluebird bio, Inc. | 108.57 Million USD | -954.609% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 12799.645% |
| Imunon, Inc. | -4.69 Million USD | 24465.471% |
| Editas Medicine, Inc. | -87.11 Million USD | 1414.34% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 91.093% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 45.423% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1199.659% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -545.798% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 3515.158% |
| Verastem, Inc. | -37.27 Million USD | 3171.517% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 86.096% |
| Waters Corporation | 1.96 Billion USD | 41.595% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 95.734% |
| Biogen Inc. | 6.28 Billion USD | 81.792% |
| Nektar Therapeutics | 210.24 Million USD | -444.616% |
| Perrigo Company plc | 3.32 Billion USD | 65.534% |
| Dynavax Technologies Corporation | 106.63 Million USD | -973.756% |
| Illumina, Inc. | 1.21 Billion USD | 5.684% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -16332.083% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1105.374% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -689.242% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -15831.543% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -202.312% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 16226.761% |
| Evolus, Inc. | 63.7 Million USD | -1697.263% |
| Adicet Bio, Inc. | -142 Million USD | 906.293% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 3211.075% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 4325.092% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -149.619% |
| FibroGen, Inc. | 56.76 Million USD | -1917.017% |
| OPKO Health, Inc. | 230.68 Million USD | -396.352% |
| Homology Medicines, Inc. | 18.43 Million USD | -6110.338% |
| Geron Corporation | 14.76 Million USD | -7656.927% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 27.775% |
| Exelixis, Inc. | -73.05 Million USD | 1667.42% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 2210.366% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 858.158% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1127.809% |
| Zoetis Inc. | 4.76 Billion USD | 75.955% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 673.013% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 11469.278% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 111.972% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 7957.535% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -8.606% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -18.239% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 945.643% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 17.082% |
| Blueprint Medicines Corporation | 702.83 Million USD | -62.911% |
| Insmed Incorporated | 721.62 Million USD | -58.671% |
| TG Therapeutics, Inc. | 17.86 Million USD | -6310.256% |
| Incyte Corporation | -3.17 Billion USD | 136.062% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -49.517% |